Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 16
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Cost-Effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Natural history/Epidemiology, Supportive care
Active
18 and over
Pharmaceutical / Industry
CR002455
NCT00264108
2.
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Natural history/Epidemiology, Supportive care
Active
18 and over
Pharmaceutical / Industry
CR005596
NCT00398749
3.
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Subjects With Metastatic Breast Cancer Receiving Standard Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Active
18 and over
Pharmaceutical / Industry
CR005143
NCT00338286
Last Modified:
7/11/2007
 
First Published:
5/23/2007
4.
Phase III Randomized Study of Recombinant Epoetin Alfa or Epoetin Beta With Versus Without Parenteral Iron in Anemic, Iron-Replete Patients With Nonmyeloid Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Active
Over 16
Other
BARTS-06/Q0605/93
ISRCTN11830961, EU-20731, 06/Q0605/93, NCT00482716
5.
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Active
Not specified
Other
2005-0890
NCT00656448
6.
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CR013651
EPOANE3018, NCT00695396
7.
Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-Cis-Retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
EPO2006-AISSM04
2006-006482-16, NCT00804050
8.
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
HOG MDS04-85
NCT00379912
9.
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Active
Over 18
Other
ETAMINE
NCT00517621
10.
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
Not specified
Other
2004-0253
NCT00520468
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute